You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
A Home Exercise Program (DVD) for Women with Infants and Young Children
SBC: KLEIN BUENDEL, INC. Topic: NIDADESCRIPTION (provided by applicant): Becoming a mother is a significant transition in a woman's life. This transition can precipitate major changes in health behaviors, like physical activity. Once a woman has a child she is much less likely to participate in regular, moderate to vigorous physical activity compared to women without children. Thus, new mothers are at risk for future weight gain and ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Anti-inflammatory and Mitotic Properties of Non-hormonal Steroids in Lung Epithel
SBC: ReveraGen BioPharma, Inc. Topic: NHLBIDESCRIPTION (provided by applicant): Asthma is a very common lung condition in children, and incidence is increasing in the US particularly in urban and minority populations. The standard of care for asthmatics is inhaled steroid, although clinical response is variable. The mechanism of efficacy of steroids in asthma is thought to be via anti-inflammatory pathways, although other anti-inflammatory ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of Airborne Particle Emissions from Commercial Products Containing Eng
SBC: APPLIED NANOTECH, INC. Topic: NIEHSDESCRIPTION (provided by applicant): This multiphase STTR project will result in a standard method to evaluate the release of airborne particles from commercial products that contain engineered nanomaterials during their use or disposal. Carbon nanotubes (CNTs) are an important class of engineered nanomaterials that are incorporated into diverse products such as sporting goods, clothes, electronic ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDType 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
AHTP-comet: development of an automated, high throughput comet assay system
SBC: ENGINEERING RESOURCES GROUP INC Topic: NIEHSPROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies
SBC: 7 Hills Pharma LLC Topic: NIAIDLeukocyte adhesion deficiency type ILADis a rare and often fatal primary immunodeficiencyIt is caused by autosomal recessive mutations in the gene ITGBwhich encodes CDthe commonsubunitof thefamily of integrin cell adhesion molecules that are specifically expressed on cells of hematopoietic origin like leukocytesAs a result of decreased function ofintegrinsleukocytes cannot extravasate from the vas ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel accurate therapy for Multiple Sclerosis
SBC: Autoimmunity Biologic Solutions, Inc. Topic: NIAIDPROJECT SUMMARY Multiple SclerosisMSis the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous systemresulting in progressive neurological dysfunctionUp to datethere is no cure for the disease and current available treatments focus on preventing future immunological attacksprimarily by su ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Mobile Peer Support for Opioid Use Disorders: Refinement of an Innovative Machine Learning Tool
SBC: BEACON TECH INC Topic: R41PROJECT SUMMARY This proposal develops a novelartificial intelligenceAIenabledmobile treatment delivery method that fulfills the need for a robustsecuretechnology based peer support platform to support patients with opioid use disordersOUDsThe majority of individuals with OUDs in the United States do not receive any formal substance use treatmentand growing evidence suggests that many OUD patients ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health